Calcium-free hemodialysis for the management of hypercalcemia

Area of Science:

• Nephrology
• Oncology
• Internal Medicine

Background:

• Traditional drug therapies for hypercalcemia of malignancy show limited efficacy or toxicity in patients with advanced renal failure.
• Severe renal failure complicates hypercalcemia management due to potential fluid overload with standard treatments.
• Need for effective and safe dialysis guidelines for hypercalcemia in renal failure patients.

Purpose of the Study:

• To evaluate the efficacy and safety of calcium-free hemodialysis for hypercalcemia in patients with renal failure.
• To establish guidelines for optimal dialysis prescription in this patient population.
• To determine the relationship between dialysis dose and calcium reduction.

Main Methods:

• Calcium-free hemodialysis was performed in 6 hypercalcemic patients with renal failure unresponsive to saline diuresis.
• Utilized a specific calcium-free dialysate composition (Na 135, K 2.5, Cl 108, Mg 0.75, HCO3 30 mmol/l).
• Measured plasma calcium, ionized calcium, and Kt/V urea to assess treatment effectiveness and dialysis adequacy.

Main Results:

• Mean plasma calcium decreased significantly from 2.92 to 2.16 mmol/l after 2-3 hours of hemodialysis.
• Ionized calcium also decreased, with no observed hypocalcemic symptoms or adverse effects.
• A strong positive correlation (r=0.92, p<0.01) was found between plasma calcium decrease and Kt/V urea.

Conclusions:

• Calcium-free hemodialysis is a viable and indicated treatment for hypercalcemia in patients with severe renal failure.
• This method is particularly useful when large-volume fluid administration is contraindicated.
• Kt/V urea serves as a reliable predictor for the extent of plasma calcium reduction during this procedure.